The Journal cites similar increases for Ofirmev pain injections and Vimovo
pain tablets after new companies acquired the rights.
Horizon's portfolio already includes Vimovo
, which is approved as a treatment for symptoms of osteoarthritis and rheumatoid arthritis, stated Walbert.
The PPI products listed in the communication are AcipHex (rabeprazole sodium); Dexi-lant (dexlansoprazole); Nexium (esomeprazole magnesium); omeprazole over-the-counter (OTC); Prevacid (lansoprazole) and OTC Prevacid 24hr; Prilosec (omeprazole) and its OTC product, Protonix (pantoprazole sodium); Vimovo
(esomeprazole magnesium and naproxen); and Zegerid (omeprazole and sodium bicarbonate) and its OTC product.
For example, AstraZeneca's Vimovo
(naproxen/esomeprazole) was approved in April, with an indication of "relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID associated gastric ulcers.
A September 23, 2015 note issued by Express Scripts, one of the largest managers of drug formularies, to its clients criticizes Horizon's price increases, comparing Horizon to Turing Pharmaceuticals, and notes that Horizon, after purchasing the rights to Vimovo
and with its own product, Duexis, "soon increased the prices on these older products more than tenfold.
As of the end of Q3 2012, VIMOVO
has been filed for regulatory approval in 80 countries, approved in 60, and commercially launched in 40 countries.
He also pointed to successes such as Vimovo
15 after Chicago Tribune reported that CVS Caremark or Express Scripts are planning to announce next month that DUEXIS and VIMOVO
would be removed from their formularies and will be placed on their exclusion lists effective January 1, 2015.
In contrast, only 44 percent of MCO pharmacy directors indicate that AstraZeneca/Pozen's fixed-dose combination Vimovo
is listed as a pharmacy benefit, likely due to the multitude of generic equivalents available.
Horizon Pharma) announced the availability of Horizon-labeled VIMOVO
(naproxen/esomeprazole magnesium) tablets in US, for the relief of signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis and to decrease the risk of stomach (gastric) ulcers in patients at risk of developing stomach ulcers from treatment with non-steroidal anti-inflammatory drug (NSAIDs).
As of the end of Q2 2012, VIMOVO
has been filed for regulatory approval in 78 countries, approved in 58, and commercially launched in 30 countries.
rights to VIMOVO
(naproxen/esomeprazole magnesium) delayed-release tablets from AstraZeneca AB.